Medical News Podcast

This episode highlights FDA approval of the first-in-class RAS inhibitor daraxonrasib for metastatic pancreatic adenocarcinoma, concerning gaps in cervical cancer screening and HPV vaccination among younger women, and new evidence defining which patients may benefit most from coronary artery calcium scoring alongside the PREVENT cardiovascular risk calculator.

Drs. Garg and Mehta discuss how advances in vitrectomy technology, imaging, and heads-up display systems are changing surgical decision-making and improving outcomes for diabetic retinopathy, tractional retinal detachments, and visually significant floaters. They emphasize earlier surgical intervention in select diabetic cases, careful patient selection and counseling, and the importance of ergonomics and visualization tools for both surgeon longevity and teaching.

Drs. Ungar and Cices discuss how to interpret long-term safety data for systemic therapies in moderate-to-severe atopic dermatitis, emphasizing the importance of balancing safety signals against the harms of uncontrolled chronic inflammation. They highlight real-world evidence—especially for JAK inhibitors and biologics like dupilumab—as increasingly reassuring, while stressing individualized risk assessment based on patient age, comorbidities, and background cardiovascular risk.

Drs. Berger and Denny review recent stroke conference data on Factor XIa inhibitors and evolving strategies for secondary stroke prevention. They highlight image-guided extended‑window tenecteplase to broaden reperfusion eligibility.

Drs. Montesi and Martinez discuss how the emerging PRIME-PPF clinical cohort study and biomarker research will sharpen definitions of disease progression and transform treatment decisions in non-IPF ILD. They highlight the potential for clinicians to use integrated data (eg, symptoms, physiology, imaging, and circulating proteomic signatures) to initiate antifibrotic and combination therapies earlier, tailoring them to individual patients while also balancing side effects and standard immunomodulatory care.

This episode highlights three clinically relevant developments: positive phase 3 results for individualized mRNA neoantigen therapy plus pembrolizumab after melanoma surgery, emerging MRI and AI approaches that may identify Alzheimer’s-related brain changes years earlier, and substantial LDL-C treatment gaps under the 2026 ACC/AHA dyslipidemia guideline. Together, the findings underscore advances in precision oncology, early neurodegenerative risk detection, and cardiovascular prevention.

Drs. Wise and Stohl discuss how truly effective care depends not just on advanced therapies, but also on humanistic, honest conversations about reproductive health and medication adherence. They highlight that patients—especially women of childbearing age and those from disadvantaged backgrounds—need ongoing, nuanced dialogue and genuine rapport in addition to a prescription.

Drs. Ghia and Scarfò discuss how CAR T-cell therapy is emerging as a powerful option for high-risk CLL and Richter transformation, especially in patients who have failed BTK and BCL-2 inhibitors. They stress that achieving deep remissions, choosing the right patients, and referring early to specialized centers are critical to improving outcomes.

Drs. de Feria and Owens review emerging data on cardiac myosin inhibitors for obstructive hypertrophic cardiomyopathy, from adolescent therapy to interruption and reinitiation of treatment. They highlight impacts on left ventricular outflow tract gradients, symptoms, biomarkers, and practical periprocedural management.

Drs. Mehta and Garg cover how to counsel patients about intravitreal injections, emphasizing communication strategies, comfort measures, and the crucial role of office staff in creating a reassuring experience. They also review long-term treatment adherence, infection risk mitigation, and evidence supporting alcohol-free chlorhexidine as a better-tolerated antiseptic than povidone-iodine.

This episode examines controversial proposed changes to the U.S. childhood vaccine schedule amid a 35-year high in measles cases, along with medical society concerns about evidence and access. It also reviews positive phase 3 topline data for lysergide in generalized anxiety disorder, updated colorectal cancer screening guidance that now includes blood-based testing, and the CHIPS trial showing refrigerated platelets may safely extend storage to 21 days and improve access in rural and community hospitals.

Drs. Cices and Ungar discuss how they personalize biologic therapy for atopic dermatitis, especially in older adults, young patients, and those with complex comorbidities. They compare targeted biologics and JAK inhibitors, highlighting options like dupilumab, lebrikizumab, tralokinumab, and nemolizumab, and emphasize shared decision-making to align treatment with each patient’s lifestyle, comorbidities, and priorities.

Drs. Griffiths and Chase explain type 2–high asthma as a multisystem inflammatory disease that often coexists with conditions like allergic rhinitis, sinus disease with polyps, eczema, food allergies, and eosinophilic esophagitis. They emphasize the importance of recognizing type 2–high patterns through history and biomarkers; they also discuss the roles of multidisciplinary care, optimized inhaler use, reduced steroid exposure, and targeted biologic therapy when asthma remains uncontrolled.

This episode examines new evidence comparing omalizumab with multiallergen oral immunotherapy for multiple food allergies, finding that omalizumab may offer better tolerability and treatment completion. It also reviews the ICECAP trial, which found no neurologic benefit from extending hypothermia after out-of-hospital cardiac arrest, and the SOLARIS trial, in which high-dose vitamin D3 did not improve outcomes in metastatic colorectal cancer.

Drs. Denny and Berger review how to optimize continuity of care and secondary stroke prevention as patients transition from hospital to home. They emphasize multidisciplinary outpatient stroke care, psychosocial needs, and safe return to community roles.

Drs. Owens and de Feria discuss strategies to identify latent LVOTO in hypertrophic cardiomyopathy and avoid misclassifying patients as non‑obstructive. They review diagnostic echo maneuvers and outline evolving pharmacologic and interventional treatment pathways.

This episode reviews four clinically relevant studies: emerging NaV1.8 inhibitors as promising non-opioid therapies for acute pain, a once-weekly oral HIV maintenance regimen demonstrating noninferiority to daily treatment, evidence supporting abbreviated dual antithrombotic therapy after PCI in selected patients with atrial fibrillation, and a meta-analysis showing limited benefit of oral antihistamines for atopic dermatitis. Together, these studies highlight evolving evidence that may influence prescribing practices across multiple specialties

Drs. Wise and Stohl discuss emerging cell therapies for refractory lupus, focusing on the CASTLE trial and its promising early results in resetting the immune system and achieving treatment-free remission. They balance enthusiasm with caution, stressing unknown long-term safety, practical, and logistical barriers, and the need to avoid overselling these therapies as a near-term cure.

Drs. Buse and Bonakdar discuss how migraine is deeply intertwined with mental health conditions such as depression and anxiety, forming a powerful “multimorbidity” cluster that can intensify pain, disability, and stigma. By combining compassionate, stigma-free communication with evidence-based tools—from simple screening questions (such as PHQ-9, GAD-7, and anhedonia prompts) to pharmacologic and behavioral therapies—clinicians can meaningfully improve both migraine and mood outcomes for their patients.

Drs. Alexander and Witteles discuss emerging data on transthyretin amyloid cardiomyopathy therapies, emphasizing early initiation of disease-modifying treatment and the prognostic value of functional measures such as the six-minute walk test. They also highlight observational evidence that aggressive cardiometabolic management, including use of newer antidiabetic agents, may further reduce residual cardiovascular risk in patients with ATTR-CM and diabetes.

Drs. Montesi and Martinez explore how to define and monitor PPF, especially in non-IPF ILD. They describe advances in recognizing progression and the use of antifibrotic therapy, while also highlighting ongoing controversy over exact criteria and emphasizing the need to combine symptoms, lung function (FVC, DLCO), and CT imaging for careful, regular follow-up.

This episode reviews the ongoing Cyclospora outbreak and emphasizes the importance of targeted diagnostic testing for patients with persistent summer diarrhea, highlights evidence supporting family-based behavioral treatment for childhood obesity in primary care, and examines a new meta-analysis comparing the cardiometabolic benefits of GLP-1 receptor agonists beyond weight loss. Together, these studies reinforce practical, evidence-based approaches to infectious disease, pediatric obesity, and personalized obesity management.

Drs. Garg and Mehta focus on challenges and solutions in providing retinal care for patients—especially those with diabetes—including barriers like socioeconomic factors, transportation, insurance, and the need for coordinated, team-based care with other medical specialists. They highlight initiatives such as diabetic eye screening days and emerging technologies like tele-ophthalmology, home OCT, and AI-driven screening and monitoring to improve access, continuity of care, and visual outcomes.

Drs. Bunick and Shahriari discuss the emerging role of the OX40/OX40L pathway in atopic dermatitis, highlighting how targeting antigen-specific T cells may rebalance the immune system and potentially induce durable, off-drug remission. They review promising phase 2 and 3 data for agents like rocatinlimab and amlitelimab, emphasize encouraging safety profiles, and explore future innovations such as combination and bispecific approaches to improve both speed and durability of disease control.

Drs. Berger and Denny discuss modern secondary prevention after non-cardioembolic ischemic stroke, focusing on short dual antiplatelet courses and individualized agent choice. They emphasize structured vascular risk management and look ahead to newer, safer antithrombotic options.

Drs. Chang and Cohen discuss how MRD has become an important tool for assessing how well patients with CLL respond to treatment, beyond what standard blood tests can show. They conclude that although MRD is very useful in research and can help inform conversations with patients, it is not yet clear how or whether it should routinely guide real-world treatment decisions.

This episode reviews new evidence supporting extended DAPT beyond one year for selected patients after multivessel PCI, the role of MRD-guided decisions for maintenance lenalidomide in multiple myeloma, adjuvant ensartinib for resected ALK-positive NSCLC, and emerging data on semaglutide and combination therapy for MASH-related cirrhosis. The studies highlight how precision medicine continues to refine treatment duration, biomarker-driven care, and therapeutic selection across multiple specialties.

This episode reviews new evidence on online GLP-1 prescribing practices, aspirin-only thromboprophylaxis after hip and knee arthroplasty, unexpected protection against gonorrhea from meningococcal B vaccination, and a cannabinoid formulation for agitation in advanced dementia. The studies highlight evolving approaches to obesity care, postoperative management, infectious disease prevention, and palliative dementia treatment with important implications for clinical practice.

Drs. Martinez and Montesi discuss how treatment for ILD, IPF, and PPF has shifted from “nothing we can do” to a complex, rapidly expanding toolbox that now includes multiple antifibrotic options and emerging combination strategies. They stress that these drugs slow progression but don’t cure disease, so real-world decisions hinge on side effects, quality of life considerations, patient goals, and the often frustrating realities of insurance coverage and cost.

Randomized evidence suggests that routinely used mucoactive therapies may no longer have a role in mechanically ventilated ICU patients, while a large comparative effectiveness study indicates GLP-1 receptor agonists may offer superior cardiovascular and atrial fibrillation outcomes compared with SGLT2 inhibitors in patients with both AF and type 2 diabetes. We also highlight a promising blood-based RNA biomarker panel that may predict Alzheimer's symptom onset several years before cognitive decline, potentially improving patient selection for emerging disease-modifying therapies.

Drs. Shahriari and Bunick discuss the emerging promise of bi- and tri-specific biologics for atopic dermatitis, aiming to bridge the gap between highly targeted biologics and broad JAK inhibitors by more comprehensively blocking key cytokine pathways. They highlight early data, such as with galvokimig, suggesting potentially higher efficacy and the possibility of improved safety and reduced paradoxical side effects, while emphasizing that final positioning in treatment will depend on forthcoming phase 2 and 3 trial results.

Drs. Witteles and Alexander discuss emerging data in transthyretin amyloid cardiomyopathy, highlighting durable survival benefits with long-term transthyretin-stabilizing therapy and the prognostic impact of atrial arrhythmias. They also review sex-related differences in phenotype that may contribute to under-recognition in women and emphasize earlier diagnosis with more nuanced, holistic management strategies.

This discussion between migraine specialists Dr. Bonakdar and Dr. Buse explores how evidence-based behavioral therapies, like CBT, biofeedback, mindfulness, and relaxation plus Complementary and Integrative Medicine approaches such as acupuncture, physical therapy, and key nutritional supplements, can meaningfully reduce migraine frequency and improve quality of life. They emphasize tailoring these options to patient preferences and medical profiles, and combining them with modern migraine medications for a personalized, comprehensive care plan.

Drs. Kalunian and McMahon explain how inflammation in areas of interstitial fibrosis and tubular atrophy (i-IFTA) in lupus nephritis is not inert scarring, but rather an active, prognostically powerful process that strongly predicts the decline of estimated glomerular filtration rate. They argue that recognizing and routinely scoring i-IFTA could transform clinical practice by shifting focus beyond glomerular lesions to the tubulointerstitial compartment, opening new avenues for risk stratification and potentially for targeted therapy.

Artificial intelligence may soon help clinicians prevent inpatient hypoglycemia before it occurs, while new decade-long follow-up data suggest CAR-T therapy may provide durable cures for selected patients with B-cell lymphoma. We also review a personalized statin muscle-risk calculator designed to improve shared decision-making and highlight new evidence supporting consistent resistance training as an important strategy for long-term type 2 diabetes prevention.

Drs. Newhall and Gupta discuss how biologic therapies are transforming care for patients with multiple allergic diseases—such as asthma, atopic dermatitis, nasal polyps, food allergy, and eosinophilic esophagitis—while also making treatment decisions more complex. They explain how they choose among biologics like dupilumab, omalizumab, IL‑5 blockers, and TSLP inhibitors by focusing on biomarkers, age, comorbidities, and which condition most affects the patient’s quality of life.

Drs. Newhall and Gupta discuss how biologic therapies are transforming care for patients with multiple allergic diseases—such as asthma, atopic dermatitis, nasal polyps, food allergy, and eosinophilic esophagitis—while also making treatment decisions more complex. They explain how they choose among biologics like dupilumab, omalizumab, IL‑5 blockers, and TSLP inhibitors by focusing on biomarkers, age, comorbidities, and which condition most affects the patient’s quality of life.

This episode of the PeerDirect Medical News Podcast highlights three studies with potential implications for prevention, pulmonary medicine, and infectious disease management. Topics include the first national-level evidence that HPV vaccination prevents cervical cancer deaths, Phase III data showing tezepelumab can reduce chronic oral corticosteroid use in severe asthma while maintaining disease control, and new evidence supporting cefazolin as a safer treatment option for MSSA bacteremia with comparable survival outcomes and less nephrotoxicity.

Drs. Cohen and Chang review how CLL and its treatments weaken the immune system and lead to poorer responses to vaccines. Even though vaccine protection is often reduced, the experts emphasize that vaccination remains a key strategy for infection prevention, alongside careful timing around therapy and proactive counseling for patients and their families.

Drs. Waks and Sammons discuss how new long-term data and key updates in the NCCN Guidelines® are reshaping treatment strategies for HER2+ breast cancer in both early-stage and metastatic settings. They highlight the growing role of T-DXd, including its benefits, risks, and optimal patient selection, alongside how to sequence it with other HER2-directed therapies like pertuzumab and T-DM1.